APA (7th ed.) Citation

Moore, K., Konecny, G., Martin, L., Floquet, A., O'Malley, D., Colombo, N., . . . Van Gorp, T. (2022). MIRASOL: A randomized, open-label, phase 3 study of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate-alpha (FRα) expression (297). Gynecologic Oncology, 166, S156. https://doi.org/10.1016/S0090-8258(22)01518-9

Chicago Style (17th ed.) Citation

Moore, Kathleen, et al. "MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine Vs. Investigator's Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate-alpha (FRα) Expression (297)." Gynecologic Oncology 166 (2022): S156. https://doi.org/10.1016/S0090-8258(22)01518-9.

MLA (9th ed.) Citation

Moore, Kathleen, et al. "MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine Vs. Investigator's Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate-alpha (FRα) Expression (297)." Gynecologic Oncology, vol. 166, 2022, p. S156, https://doi.org/10.1016/S0090-8258(22)01518-9.